Ashling Wahner

Articles

NALIRIFOX Approval Revitalizes Pancreatic Cancer Management

February 19th 2024

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

February 18th 2024

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Hematologists and Patients Come Together for Patient-Focused GVHD Discussions

February 17th 2024

Carrie L. Kitko, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.

Active Surveillance Is a Safe and Acceptable Treatment Alternative in Select D-TGCT

February 16th 2024

R. Lor Randall, MD, discusses the adequacy of active surveillance for select patients with diffuse-type tenosynovial giant cell tumor.

Standard-of-Care Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

February 13th 2024

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

FDA Accepts NDA Resubmission for Dasynoc in CML

February 13th 2024

A new drug application for Dasynoc, a protein kinase inhibitor product candidate for patients with chronic myeloid leukemia, has been accepted by the FDA.

FELIX Pooled Analysis Findings Potentiate Further Obe-Cel Development in B-ALL

February 12th 2024

Michael R. Bishop, MD, discusses the rationale for and key findings from the FELIX trial of obe-cel in B-cell acute lymphoblastic leukemia.

FDA Grants Breakthrough Therapy Designation to AlphaMedix for Gastroenteropancreatic Neuroendocrine Tumors

February 12th 2024

AlphaMedix has received breakthrough therapy designation from the FDA for use in select patients with gastroenteropancreatic neuroendocrine tumors.

rPFS and cPFS May Act as Surrogate OS End Points in Phase 3 mHSPC Clinical Trials

February 9th 2024

Radiographic and clinical progression-free survival may be surrogates for overall survival in hormone-sensitive prostate cancer clinical trials.

HIPEC Plus Surgery Prolongs PFS and OS in Stage III Ovarian Cancer

February 8th 2024

Hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery improved progression-free survival in stage III epithelial ovarian cancer.

EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management

February 7th 2024

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.

Investigators Set to Explore Selinexor Monotherapy or Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

January 31st 2024

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

KRAS G12C–Targeted Therapies May Move Earlier in the mCRC Treatment Sequence

January 31st 2024

Rona Yaeger, MD, discusses a study of second-line sotorasib plus panitumumab in patients with KRAS G12C–mutated colorectal cancer.

Targeted Agents and Combination Therapies May Open Doors in MDS Management

January 30th 2024

Talha Badar, MBBS, MD, discusses the FDA approval of ivosidenib for patients with myelodysplastic syndrome and the future management of this disease.

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Positive Solid Tumors

January 29th 2024

The FDA has granted priority review to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive advanced solid tumors.

Adjuvant Pembrolizumab Improves DFS, But Not OS, in Locally Advanced/Muscle-Invasive Urothelial Carcinoma

January 27th 2024

Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.

SGO Winter Meeting Spotlights Key Developments and Debates Across Gynecologic Oncology

January 26th 2024

Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.

Real-World Data Confirm the Incidence of ADC-Related Ocular Toxicities in Ovarian Cancer

January 26th 2024

Susan Marie Lang, MD, discusses real-world data on the incidence of ocular toxicities in patients with ovarian cancer receiving mirvetuximab soravtansine.

Pirtobrutinib Expands MCL Armamentarium, Although Sequencing Questions Remain

January 24th 2024

William Pearse, MD, discusses how the FDA approval of pirtobrutinib for relapsed/refractory mantle cell lymphoma has advanced BTK inhibitor treatment.

MDS Research Expands Treatment Options Across Disease Subsets

January 24th 2024

Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.